Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

医学 细胞因子释放综合征 梅尔法兰 内科学 化疗方案 自体干细胞移植 化疗 养生 美罗华 布苏尔班 移植 临床研究阶段 外科 环磷酰胺 肿瘤科 胃肠病学 淋巴瘤 癌症 免疫疗法 嵌合抗原受体
作者
Wei Liu,Hesong Zou,Yan Xu,Huimin Liu,Chenxing Du,Rui Lv,Wenyang Huang,Weiwei Sui,Shuhua Yi,Lulu Liu,Lugui Qiu,Jianxiang Wang,Dehui Zou
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 7472-7473
标识
DOI:10.1182/blood-2022-166451
摘要

Background: We have previously reported the preliminary results of a phase 1/2 clinical trial of administrating CNCT19 (a second-generation anti-CD19 CAR T-cell) following high-dose chemotherapy and autologous stem-cell transplantation (HDT/ASCT) in large B-cell lymphoma (LBCL) patients with diseases refractory to first-line and/or subsequent lines of chemotherapy. Eight of 10 (80%) patients achieved complete response (CR), and the estimated proportion of progression-free survival (PFS) and overall survival (OS) at 12 months was 66.7% and 77.1%, respectively (Wei liu et al. ASH 2019, 2020). Here we reported this study's updated enrollment, efficacy, and follow-up. This trial was registered at www.chictr.org.cn as ChiCTR1900025419. Methods: Patients with LBCL with a history of refractory to first-line rituximab-containing anthracycline-based chemotherapy and/or subsequent salvage chemotherapy were eligible for this study. Conditioning regimen of GBC/M (Gemcitabine 600 mg/m2/h, infused for 3 hours with loading bolus of 75 mg/m2, day -7, -3, busulfan 105 mg/m2, day -7 until -5, cyclophosphamide 45mg/kg or melphalan 60 mg/m2, day -3, -2) was administered once the CNCT19 product was available. Autologous stem cells were infused on day 0, and CNCT19 cells were infused on day +3 (±1 day). Cytokine release syndrome (CRS) and CAR-T-cell-related encephalopathy syndrome (CRES) were graded according to the CAR-T-cell-therapy-associated TOXicity (CARTOX) Working Group criteria. Results: From December 2017 through May 2021, 21 subjects were consecutively enrolled in this study. CNCT19 cells were successfully manufactured for 20 subjects and administered to 18 subjects. The median age was 44 (range 23 to 64), and 56% were male. Patients included 11 (67%) with diffuse large B-cell lymphoma (not otherwise specified), 4 (22%) with high-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangement, 2 (11%) with primary mediastinal large B-cell lymphoma and 1 (6%) with transformed follicular lymphoma. The median number of lines of prior therapy was 3 (range, 2 to 5). Eighty-nine percent of patients had a history of refractory to first-line immunochemotherapy of R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, prednisone) or R-DA-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and adriamycin), and 72% were refractory to subsequent platinum-based salvage therapy. TP53 deletion and/or mutation were detected in 7 of 11 (64%) patients. The median dose of infused stem cells was 2.6×106 (range, 1.8~8.7×106) per kilogram of body weight and the median dose of infused CNCT19 cells was 2×106 (range, 1.6~4.0×106) per kilogram of body weight. The CRS occurred in 16 patients (89%), and all were low grades (grade 1, 83%; grade 2, 6%). CRES occurred in two patients on day 5 and day 6 after CNCT19 infusion, respectively. Both of the ICANS were grade 4 and resolved completely after glucocorticoids treatment. We did not observe any unexpected toxicity or treatment-related death throughout the therapy. The median times to neutrophil and platelet recovery were ten days (range, 8 to 30 days) and 16.5 days (range, 8 to 265 days) after stem cells reinfusion, respectively. As of July 26, 2022, the median follow-up from CNCT19 infusion to the data-cutoff date was 28.2 (95% CI 16.9-39.1) months. The best overall response rate was 94.4%, with a best CR rate of 72.2%. The median PFS, duration of response (DOR), disease-free survival (DFS) and OS were not reached, and the probability of 2-year PFS, DOR, DFS and OS were 59.3% (95% CI 32.5%-78.4%), 63.5% (95% CI 35.9%-81.8%), 74.1% (95% CI 39.1%-90.9%) and 64.2% (95% CI 36.2%-82.4%), respectively. Of the patients who were in durable response at three months or six months post CNCT19 infusion, 66.7% and 83.3% were in ongoing response at the date of data cutoff, respectively. Conclusions: CNCT19 could be safely administered following HDT/ASCT in patients with relapsed or refractory LBCL. The strategy of combining CAR T-cell therapy with HDT/ASCT might improve response rate and prolong survival compared to CAR T-cell therapy alone.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
有魅力夜天完成签到 ,获得积分10
刚刚
vvr完成签到 ,获得积分10
刚刚
刚刚
smh发布了新的文献求助10
刚刚
进击的吐司完成签到,获得积分10
1秒前
inspirx完成签到,获得积分10
1秒前
科研通AI6.4的应助被朴实归尘采纳,获得30
1秒前
Wangke发布了新的文献求助10
2秒前
文泽完成签到,获得积分10
2秒前
清脆的白凡完成签到,获得积分10
3秒前
3秒前
3秒前
鹿若颜完成签到,获得积分10
3秒前
5秒前
外向幻桃完成签到 ,获得积分10
5秒前
初夏发布了新的文献求助10
5秒前
loulang9完成签到,获得积分10
6秒前
思源的应助被周周采纳,获得10
6秒前
原野发布了新的文献求助10
7秒前
qluo001完成签到,获得积分10
7秒前
小fool完成签到,获得积分10
8秒前
1793480753完成签到,获得积分10
9秒前
朴素睿渊发布了新的文献求助10
9秒前
科研通AI6.4的应助被告白气球采纳,获得10
9秒前
苏卷卷完成签到 ,获得积分10
9秒前
旺旺仙贝完成签到 ,获得积分10
11秒前
wanci的应助被斩棘采纳,获得10
11秒前
12秒前
李盛男完成签到,获得积分10
12秒前
13秒前
今后的应助被嫑嫑采纳,获得10
13秒前
zhang完成签到,获得积分10
13秒前
XwK完成签到,获得积分10
13秒前
14秒前
Hus11221完成签到,获得积分10
14秒前
南颂完成签到,获得积分10
14秒前
Rr完成签到,获得积分10
14秒前
金栀子完成签到,获得积分10
15秒前
Jun举报小唐的求助涉嫌违规
15秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185743
求助须知:如何正确求助?哪些是违规求助? 9574397
关于积分的说明 21836038
捐赠科研通 7783520
什么是DOI,文献DOI怎么找? 3434643
关于科研通互助平台的介绍 2559017
邀请新用户注册赠送积分活动 2481440